Gerber LLC’s Monopar Therapeutics MNPR Stock Holding History

Gerber LLC’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$519K	Hold	5,601	–	–	0.24%	47
2026 Q1	$307K	Hold	5,601	–	–	0.17%	59
2025 Q4	$366K	Hold	5,601	–	–	0.2%	51
2025 Q3	$457K	Hold	5,601	–	–	0.29%	40
2025 Q2	$200K	Hold	5,601	–	–	0.14%	88
2025 Q1	$204K	Buy	+5,601	New	+$202K	0.17%	84
2024 Q3	–	Sell	-5,601	Closed	-$20.4K	–	96
2024 Q2	$20.4K	Hold	5,601	–	–	0.02%	91
2024 Q1	$19.1K	Hold	5,601	–	–	0.02%	100
2023 Q4	$9.53K	Buy	+5,601	New	+$11.3K	0.01%	92

Other funds holding MNPR

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

MIM

Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Gerber LLC's MNPR Position: Q2 2026 in Review

Gerber LLC held its Monopar Therapeutics (MNPR) position steady in Q2 2026 at 5,601 shares worth $519K. The position accounts for 0.24% of the portfolio, ranked #47.

Gerber LLC first reported a position in MNPR in Q4 2023 and has held it in 9 quarters since. 8 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

Gerber LLC held 5,601 shares of Monopar Therapeutics worth $519K as of Q2 2026.
Gerber LLC left its Monopar Therapeutics share count unchanged in Q2 2026.
Monopar Therapeutics made up 0.24% of Gerber LLC's portfolio in Q2 2026, its #47 holding.
Gerber LLC first reported a position in Monopar Therapeutics in Q4 2023 and has held it in 9 quarters since.
8 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Gerber LLC's 13F filing for Q2 2026, filed 29 Jul 2026.